Publications
2023 Publications
Cohen AT, Benson G, Bradbury CA, Choudhuri S, Hutchinson Jones N, Maraveyas A, Venugopal B, Young AM, Chapman C, McIntyre S, Burney D, Pollock KG, Morgan AR, Gabb PD, Alikhan R. A consensus viewpoint on the role of direct factor Xa inhibitors in the management of cancer-associated venous thromboembolism in the UK. Curr Med Res Opin. 2023 Mar;39(3):483-495.
Miller RJH, Chew DS, Qin L, Fine NM, Chen J, McMurray JJV, Howlett JG, McEwan P. Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure. Eur J Heart Fail. 2023 Feb;25(2):238-247.
Garcia Sanchez JJ, James G, Carrero JJ, Arnold M, Lam CSP, Pollock C, Chen HT, Nolan S, Wheeler DC, Pecoits-Filho R. Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort. Kidney Int Rep. 2023 Feb 3;8(4):785-795.
McEwan P, Harrison C, Binnie R, Lewis RD, Cohen-Solal A, Lund LH, Ohlsson M, von Haehling S, Comin-Colet J, Pascual-Figal DA, Wächter S, Dorigotti F, de Arellano AR, Ponikowski P, Jankowska EA. Impact of ferric carboxymaltose for iron deficiency at discharge after heart failure hospitalization: a European multinational economic evaluation. Eur J Heart Fail. 2023 Mar;25(3):389-398.
Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. BMC Nephrol. 2023 Mar 9;24(1):47.
McEwan P, Foos V, Martin B, Chen J, Evans M. Estimating the value of sodium-glucose cotransporter-2 inhibitors within the context of contemporary guidelines and the totality of evidence. Diabetes Obes Metab. 2023 Jul;25(7):1830-1838.
Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data
Rozenbaum MH, Begier E, Kurosky SK, Whelan J, Bem D, Pouwels KB, Postma M, Bont L. Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data. Infect Dis Ther. 2023 Jun;12(6):1487-1504.
Sugai M, Yuasa A, Miller RL, Vasilopoulos V, Kurosu H, Taie A, Gordon JP, Matsumoto T. An Economic Evaluation Estimating the Clinical and Economic Burden of Increased Vancomycin-Resistant Enterococcus faecium Infection Incidence in Japan. Infect Dis Ther. 2023 Jun;12(6):1695-1713.
Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective
de Pouvourville G, Rossignol P, Boussahoua M, Chevalier J, Gabb PD, Poulnais R, Verboux D, Rao N, Sörstadius E, Garcia Sanchez JJ. Budget Impact Analysis of Expanding Gliflozin Coverage in the CKD Population: A French Perspective. Adv Ther 40, 3751–3769 (2023).
Gordon JP, Al Taie A, Miller RL, Dennis JW, Blaskovich MAT, Iredell JR, Turnidge JD, Coombs GW, Grolman DC, Youssef J. Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia. Infect Dis Ther. 2023 Jul;12(7):1875-1889.
Barmpouni M, Gordon JP, Miller RL, Dennis JW, Grammelis V, Rousakis A, Souliotis K, Poulakou G, Daikos GL, Al-Taie A. Clinical and Economic Value of Reducing Antimicrobial Resistance in the Management of Hospital-Acquired Infections with Limited Treatment Options in Greece. Infect Dis Ther. 2023 Jul;12(7):1891-1905.
Booth D, Davis JA, McEwan P, Solomon SD, McMurray JJV, De Boer RA, Comin-Colet J, Bachus E, Chen J. The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: A European health-economic analysis of the DELIVER trial. Eur J Heart Fail. 2023 Aug;25(8):1386-1395.
Jha V, Al-Ghamdi SMG, Li G, Wu MS, Stafylas P, Retat L, Card-Gowers J, Barone S, Cabrera C, Garcia Sanchez JJ. Global Economic Burden Associated with Chronic Kidney Disease: A Pragmatic Review of Medical Costs for the Inside CKD Research Programme. Adv Ther. 2023 Jul 26.
Moreno S, Rivero A, Ventayol P, Falcó V, Torralba M, Schroeder M, Neches V, Vallejo-Aparicio LA, Mackenzie I, Turner M, Harrison C. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain. Infect Dis Ther. 2023 Jul 14.
Khair A, Brown T, Markert M, Barsøe CR, Daftary GS, Heiser PW. Highly Purified Human Menopausal Gonadotropin (HP-hMG) Versus Recombinant Follicle-Stimulating Hormone (rFSH) for Controlled Ovarian Stimulation in US Predicted High-Responder Patients: A Cost-Comparison Analysis. Pharmacoecon Open. 2023 Sep;7(5):851-860.
Gordon J, Gheorghe M, Goldenberg S, Miller R, Dennis J, Al-Taie A. Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom. Pharmacoeconomics. 2023 Aug 16.
2022 Publications
Evans M, Morgan AR, Bain SC, Davies S, Hicks D, Brown P, Yousef Z, Dashora U, Viljoen A, Beba H, Strain WD. Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice. Diabetes Ther. 2022 Feb;13(2):225-240
Shiri T, Evans M, Talarico CA, Morgan AR, Mussad M, Buck PO, McEwan P, Strain WD. The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. Vaccines. 2022; 10(2):140
McEwan P, Morgan AR, Boyce R, Green N, Song B, Huang J, Bergenheim K. Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies. J Manag Care Spec Pharm. 2022 Apr;28(4):415-424
Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently
Evans M, Morgan AR, Bain SC et al. Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently. Diabetes Ther. 2022 May;13(5):889-911
Tafesse E, Hurst M, Sugrue D, Hoskin L, Badora K, Qin L, James G, McEwan P. Serum Potassium As A Predictor Of Adverse Clinical Outcomes In Patients With Increasing Comorbidity Burden. Eur Heart J Qual Care Clin Outcomes. 2022 Jan; 8(1):61–69
Evans M, Morgan AR, Whyte MB et al. New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice. Drugs. 2022 Feb;82(2):97-108
Evans M, Lewis RD, Morgan AR et al. A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives. Adv Ther. 2022 Jan;39(1):33-43
Evans M, Morgan AR, Davies S, Beba H, Strain WD. The role of sodium-glucose co-transporter-2 inhibitors in frail older adults with or without type 2 diabetes mellitus. Age Ageing. 2022 Oct 6;51(10):afac201
Hill NR, Groves L, Dickerson C, Boyce R, Lawton S, Hurst M, Pollock KG, Sugrue DM, Lister S, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT. Identification of undiagnosed atrial fibrillation using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI) in primary care: cost-effectiveness of a screening strategy evaluated in a randomized controlled trial in England. J Med Econ. 2022 Jan-Dec;25(1):974-983
Hill NR, Groves L, Dickerson C, Ochs A, Pang D, Lawton S, Hurst M, Pollock KG, Sugrue DM, Tsang C, Arden C, Davies DW, Martin AC, Sandler B, Gordon J, Farooqui U, Clifton D, Mallen C, Rogers J, Camm AJ, Cohen AT. Identification of undiagnosed atrial fibrillation using a machine learning risk-prediction algorithm and diagnostic testing (PULsE-AI) in primary care: a multi-centre randomized controlled trial in England. Eur Heart J Digital Health 2022 Jun;3(2):195-204
Kim K, Fagerström J, Chen G, Lagunova Z, Furuland H, McEwan P. Cost effectiveness of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in patients with CKD in Norway and Sweden. BMC Nephrol. 2022 Aug 12;23(1):281
Ward T, Brown T, Lewis RD, Kliess MK, de Arellano AR, Quinn CM. The cost effectiveness of patiromer for the treatment of hyperkalaemia in patients with chronic kidney disease with and without heart failure in Ireland. Pharmacoecon Open. 2022 Sep;6(5):757-771
Waddell T, Fife K, Griffiths R, Sharma A, Dhokia P, Groves L, Hurst M, Tsang C, Sugrue D, McKenna S, Houghton J, Carroll R. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. BMC Cancer. 2022 Jun 6;22(1):617
Steg PG, Bhatt DL, James SK, Darlington O, Hoskin L, Simon T, Fox KM, Leiter LA, Mehta SR, Harrington RA, Himmelmann A, Ridderstråle W, Andersson M, Bueno H, De Luca L, Tank A, Mellström C, McEwan P. Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial. Eur Heart J Cardiovasc Pharmacother. 2022 Apr 30:pvac032
Poinas AC, Padgett K, Heus R, Perrotin F, Devlieger R. Oral misoprostol tablets (25 µg) for induction of labor: a targeted literature review and cost analysis. J Med Econ. 2022 Jan-Dec;25(1):428-436
Comparative efficacy and safety of fostemsavir in heavily treatment-experienced people with HIV-1
Anderson SJ, van Doornewaard A, Turner M, Jacob I, Clark A, Browning D, Schroeder M. Comparative efficacy and safety of fostemsavir in heavily treatment-experienced people with HIV-1. Clin Ther. 2022 Jun;44(6):886-900
Matsumoto T, Yuasa A, Miller R, Pritchard C, Ohashi T, Taie A, Gordon J. Estimating the economic and clinical value of introducing ceftazidime/avibactam into antimicrobial practice in Japan: A dynamic modelling study. Pharmacoecon Open. 2022 Sep 15:1-12
McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, Briggs A, Bergenheim K, Garcia Sanchez JJ. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022 Dec;17(12):1730-1741.
Pollock C, James G, Garcia Sanchez JJ, Carrero JJ, Arnold M, Lam CSP, Chen HT, Nolan S, Pecoits-Filho R, Wheeler DC. Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. Clin Kidney J. 2022 Jul 26;15(11):2124-2134.
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis
McEwan P, Boyce R, Sanchez JJG, Sjöström CD, Stefansson B, Nolan S, Correa-Rotter R, Rossing P, Chertow GM, McMurray JJV, Wheeler DC, Heerspink HJL. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant. 2023 May 4;38(5):1260-1270.
Zaman A, Prendergast B, Hildick-Smith D, Blackman DJ, Anderson R, Spence M, Mylotte D, Smith D, Wilding B, Chapman C, Atkins K, Pollock KG, Qureshi AC, Banning AP. An Update on Anti-thrombotic Therapy Following Transcatheter Aortic Valve Implantation: Expert Cardiologist Opinion from a UK and Ireland Delphi Group, Interventional Cardiology 2023;18:e13.
Lu X, Jarrett J, Sadler S, Tan M, Dennis J, Jairath V. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. Int J Clin Pharm. 2023 Apr;45(2):330-341.
Sandin R, Harrison C, Draica F, Wiemken TL, Ma C, Di Fusco M, Markson L, Dzingina M. Estimated Impact of Oral Nirmatrelvir;Ritonavir on Reductions in Hospitalizations and Associated Costs within High-Risk COVID-19 Patients in the US, 30 November 2022, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-2191067/v1]
Barmpouni M, Gordon JP, Miller RL, Pritchard CRJ, Dennis JW, Grammelis V, Rousakis A, Souliotis K, Poulakou G, Daikos GL, Al-Taie A. Estimating the Clinical and Economic Impact of Introducing a New Antibacterial into Greek Clinical Practice for the Management of Hospital-Acquired Infections with Limited Treatment Options. Infect Dis Ther. 2023 Feb;12(2):527-543.
McEwan P, Ponikowski P, Shiri T, Rosano GMC, Coats AJS, Dorigotti F, Ramirez de Arellano A, Jankowska EA. Clinical and economic impact of ferric carboxymaltose treatment for iron deficiency in patients stabilized following acute heart failure: a multinational study. J Med Econ. 2023 Jan-Dec;26(1):51-60.
2021 Publications
Matsumoto T, Darlington O, Miller R, Gordon J, McEwan P, Ohashi T, Taie A, Yuasa A. Estimating the Economic and Clinical Value of Reducing Antimicrobial Resistance to Three Gram-negative Pathogens in Japan. JHEOR. 2021;8(2):64-75
Shiri T, Evans M, Talarico CA, Morgan AR, Mussad M, Buck PO, McEwan P, Strain WD. Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example. Vaccines. 2021; 9(10):1180
Darlington O, Dickerson C, Evans M, McEwan P, Sörstadius E, Sugrue D, van Haalen H, Garcia Sanchez JJ. Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Adv Ther. 2021 Feb;38(2):994-1010
Bem D, Sugrue D, Wilding B, Zile I, Butler K, Booth D, Tafesse E, McEwan P. The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. Renal Failure. 2021 Jan 1;43(1):241-54.
Rozenbaum MH, Large S, Bhambri R, Stewart M, Whelan J, van Doornewaard A, Dasgupta N, Masri A, Nativi-Nicolau J. Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. Cardiol Ther. 2021 Jun;10(1):141-159
One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus
Evans M, Morgan AR, Bain SC. One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus. Diabetes Ther. 2021 Jun;12(6):1593-1604
Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
Evans M, Morgan AR, Yousef Z, Ellis G, Dashora U, Patel DC, Brown P, Hanif W, Townend JN, Kanumilli N, Moore J, Wilding JPH, Bain SC. Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors. Drugs. 2021 Jul;81(11):1243-1255
Butler K, Anderson SJ, Hayward O, Jacob I, Punekar YS, Evitt LA, Oglesby A. Cost-effectiveness and budget impact of dolutegravir/lamivudine for treatment of human immunodeficiency virus (HIV-1) infection in the United States. J Manag Care Spec Pharm. 2021 Jul;27(7):891-903
Gordon J, Stainthorpe A, Jones B, Jacob I, Hertel N, Diaz J, Yuan Y, Borrill J. Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making. Pharmacoecon Open. 2021 Dec;5(4):701-713
The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes
Strain WD, Morgan AR, Evans M. The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes. Diabetes Ther. 2021 Nov;12(11):2817-2826
Tafesse E, Hurst M, Hoskin L, Badora K, Sugrue D, Qin L, James G, McEwan P. Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. Int J Clin Pract. 2021;75(4)
McEwan P, Morgan AR, Boyce R, Bergenheim K, Gause-Nilsson I, Bhatt D, Leiter LA, Johansson PA, Mosenzon O, Cahn A, Wilding J. The cost-effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial. Diabetes Obes Metab. 2021 Apr;23(4):1020-1029
Evans, M., Morgan, A.R., Patel, D. et al. Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications. Diabetes Ther. 2021 Jan;12(1):87-105
Sekelj S, Sandler B, Johnston E, et al. Detecting undiagnosed atrial fibrillation in UK primary care: Validation of a machine learning prediction algorithm in a retrospective cohort study. Eur J Prev Cardiol. 2021 May 22;28(6):598-605
2020 Publications
Hill NR, Arden C, Beresford-Hulme L, Camm AJ, Clifton D, Davies DW, Farooqui U, Gordon J, Groves L, Hurst M, Lawton S, Lister S, Mallen C, Martin AC, McEwan P, Pollock KG, Rogers J, Sandler B, Sugrue DM, Cohen AT. Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemp Clin Trials. 2020 Oct 19;99:106191
McEwan P, Bennett H, Khunti K, et al. Assessing the cost-effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence. Diabetes Obes Metab. 2020 Dec;22(12):2364-2374
McEwan P, Darlington O, McMurray JJV, et al. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. Eur J Heart Fail. 2020 Nov;22(11):2147-2156
Lei S, Willis M, Asseburg C, Nilsson A, Tew M, Clarke P, Lamotte M, Ramos M, Shao H, Shi L, Zhang P, McEwan P, Ye W, Herman W, Kuo S, Isaman DJ, Schramm W, Sailer F, Brennan A, Pollard D, Smolen H, Leal J, Gray A, Patel R, Feenstra T, Palmer A. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. Value Health. 2020 Sep;23(9):1163-1170
Hill NR, Sandler B, Mokgokong R, Lister S, Ward T, Boyce R, Farooqui U, Gordon J. Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: Evaluation of a machine learning risk prediction algorithm. J Med Econ. 2020 Jan;23(4):386-393
Hill NR, Sandler B, Bergrath E, Milenković D, Ashaye AO, Farooqui U, Cohen AT. A systematic review of network meta-analyses and real-world evidence comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. Clin Appl Thromb Hemost. 2020 Jan;26:1076029619898764
Ward T, Sugrue D, Hayward O, McEwan P, Anderson SJ, Lopes S, Punekar Y. Oglesby A. Estimating HIV Management and Comorbidity Costs Among Aging HIV Patients in the United States: A Systematic Review. J Manag Care Spec Pharm, 2020 Feb;26(2):104-116
Bennett H, Tank A, Evans M, Bergenheim K, McEwan P. Cost‐effectiveness of dapagliflozin as an adjunct to insulin for the treatment of Type 1 Diabetes Mellitus in the UK. Diabetes Obes Metab. 2020 Jul;22(7):1047-1055
Jacob I, Butler K, Badora K, Gross, V, Beiderbeck, A, Morris S, McEwan P. Comment on ‘Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal’. Pharmacoeconomics. 2020 Jun;38(6):645-648
Gordon J, Darlington O, McEwan P, Lumley M, Taie A, Hicks M, Charbonneau C, Blake A, Hawkins N, Goldenberg S, Otter J, Wilcox M. Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission Model. Pharmacoeconomics. 2020 Aug;38(8):857-869
Gordon J, Danne T, Beresford-Hulme L, Bennet H, Tank A, Edmonds C, Thorén F, Scheerer MF, McEwan P. Adverse Changes in HbA1c, Body Weight and Insulin Use in People with Type 1 Diabetes Mellitus Following Dapagliflozin Discontinuation in the DEPICT Clinical Trial Programme. Diabetes Ther. 2020 May;11(5):1135-1146
What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient
Strain WD, Tsang C, Hurst M, McEwan P, Unadkat M, Meadowcroft S, Shardlow R, Evans M. What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient. Diabetes Ther. 2020 Jun;11(6):1381-1395
Gordon J, Beresford-Hulme L, Bennett H, Tank A, Edmonds C, McEwan P.Relationship Between Hypoglycaemia, Body Mass Index and Quality of Life Among Patients With Type 1 Diabetes: Observations From the DEPICT Clinical Trial Programme. Diabetes Obes Metab. 2020 May;22(5):857-865
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C. Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma. Clinicoecon Outcomes Res. 2020;12:241-252
Palaka E, Grandy S, van Haalen H, McEwan P, Darlington O. The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes - A Systematic Literature Review. Int J Nephrol. 2020:7692376
Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, Eisen T, Matakidou A, Gordon J. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC Cancer. 2020;20(1):670
Associations between serum potassium and adverse clinical outcomes: a systematic literature review
Palaka E, Grandy S, Darlington O, McEwan P, van Doornewaard A. Associations between serum potassium and adverse clinical outcomes: a systematic literature review. Int J Clin Pract. 2020 Jan;74(1):e13421
Kaloyannidis P, Hertzberg M, Webb K, Zomas A, Schrover R, Hurst M, Jacob I, Nikoglou T, Connors JM. Brentuximab vedotin for the treatment of patients with relapsed or refractory Hodgkin lymphoma after autologous stem cell transplantation. Br J Haematol. 2020 Feb;188(4):540-549
Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
Evans M, Hicks D, Patel D, Patel V, McEwan P, Dashora U. Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes Therapy. Diabetes Ther. 2020 Jan;11(1):37-52
2019 Publications
Pochopien M, Beiderbeck A, McEwan P, Zur R, Toumi M, Aballéa S. Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies. BMC Health Services Research. 2019 Dec;19(1):22
Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. 2019 Apr;6(2):280-290
The value of maintaining normokalaemia and enabling RAASi therapy in Chronic Kidney Disease
Evans M, Palaka E, Furuland H, Bennett H, Linde C, Qin L, McEwan P, Bakhai A. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrology. 2019 Dec;20(1):31.
Bennett H, McEwan P, Hamilton K, O'Reilly K. Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD. BMC Nephrology. 2019 Apr 23;20(1):136
Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M, Zhang P, Ye W, Lizheng S, Herman W, McEwan P. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics. 2019 Nov;37(11):1305-1312
Strain WD, McEwan P, Howitt H, Meadowcroft S. Retrospective Database Analysis Evaluating the Clinical Outcomes of Changing Treatment of People with Type 2 Diabetes Mellitus (T2DM) from Other DPP-4 Inhibitor Therapy to Alogliptin in a Primary Care Setting. Diabetes Ther. 2019 Aug;10(4):1499-1507
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Yuan Y, Juarez-Garcia A, Tyas D, Pritchard C. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. J Med Econ. 2019 Mar;1:1-4.
Foos V, Wang K, McEwan P, Zhang Y, Xin P, Jiang X, Qu S, Xiong T, De Moor R, Ramos M, Lamotte M. Assessing the burden of type 2 diabetes in China considering the current status-quo management and implications of improved management using a modeling approach. Value in health regional issues. 2019 May 1;18:36-46.
Lacoin L, Hurst M, Hill NR,, Gordon J, Geretti AM, Aspinall R, Corless L, Gao-Du Y, Mistry L, Mutimer D. Evolution of the burden of active hepatitis C virus infection in England from September 2015 to September 2016: a repeated cross-sectional analysis. BMJ Open. 2019 August 5; 9(8).
What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?
Evans M, Morgan AR, Yousef Z. What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer? Diabetes Ther. 2019 Oct;10(5):1719-1731
Sugrue DM, Ward T, Rai S, McEwan P, van Haalen HGM. Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. Pharmacoeconomics. 2019 Dec;37(12):1451-1468
Predicting Atrial Fibrillation in Primary Care Using Machine Learning
Hill NR, Ayoubkhani D, McEwan P, Sugrue DM, Farooqui U, Lister S, Lumley M, Bakhai A, Cohen AT, O'Neill M, Clifton D, Gordon J. Predicting atrial fibrillation in primary care using machine learning. PLoS One. 2019 Nov 1;14(11):e0224582
Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc. 2019 Nov 19;8(22):e012655
2018 Publications
McEwan P, Wilton HB, Ong AC, Ørskov B, Sandford R, Scolari F, Cabrera MC, Walz G, O’Reilly K, Robinson P. A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrology. 2018 Dec;19(1):37
McEwan P, Bennett H, Bolin K, Evans M, Bergenheim K. Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence. Diabetic Med. 2018 May;35(5):557-66
Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, Monfared AT, Yuan Y, Juarez-Garcia A, Tyas D, Lees M. Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. Clinicoecon Outcomes Res. 2018;10:139
Prospective utility study of patients with multiple cardiovascular events
Pockett RD, McEwan P, Ray J, Tran I, Shutler S, Martin S, Yousef Z, Bakhai A. Prospective utility study of patients with multiple cardiovascular events. J Med Econ. 2018 Jun 3;21(6):616-21
Gordon J, McEwan P, Idris I, Evans M, Puelles J. Treatment choice, medication adherence and glycemic efficacy in people with type 2 diabetes: a UK clinical practice database study. BMJ Open Diabetes Research and Care. 2018 May 1;6(1):e000512
Chen W, Ward T, Tan MP, Yan J, Wang PF, Wygant GD, Gordon J. Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. J Comp Eff Res. 2018 Aug;7(8):785-795
Furuland H, McEwan P, Evans M, Linde C, Ayoubkhani D, Bakhai A, Palaka E, Bennett H, Qin L. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrology. 2018 Dec;19(1):211
Bakhai A, Palaka E, Linde C, Bennett H, Furuland H, Qin L, McEwan P, Evans M. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. J Med Econ. 2018 Dec;21(12):1172-1182
2017 Publications
Fathi H, Clark A, Hill NR, Dusheiko G. Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review. BMC Infect Dis. 2017 Dec;17(1):722
Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ. 2017 Nov 1;18(8):1001-11
McEwan P, Webster S, Ward T, Brenner M, Kalsekar A, Yuan Y. Estimating the cost-effectiveness of daclatasvir+sofosbuvir versus sofosbuvir+ribavirin for patients with genotype 3 hepatitis C virus. Cost Eff Resour Alloc. 2017 Jul 21;15:15
Ward T, Webster S, Mishina S, McEwan P, Wygant G, Wang P. Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value Health Reg Issues. 2017 May;12:1-6
Gordon J, McEwan P, Evans M, Puelles J. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2017 May; 19(5): 644–653
An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus
McEwan P, Bennett H, Qin L, Bergenheim K, Gordon J, Evans M. An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 May;19(5):628-634
McEwan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M and Gordon J. A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. Eur J Gastroenterol Hepatol. 2017 Feb;29(2):208-214
Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea
Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS One. 2017 Jan 6;12(1)
Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug Investig. 2017 Jan;37(1):61-70
The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit.
Selvapatt N, Ward T, Harrison L, Lombardini J, Thursz M, McEwan P, Brown A. The cost impact of outreach testing and treatment for hepatitis C in an urban Drug Treatment Unit. Liver Int. 2017 Mar;37(3):345-353
2016 Publications
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2016 Mar;46(5):423-33
Ward T, Gordon J, Bennett H, Webster S, Sugrue D, Jones B, Brenner M, McEwan Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences. Public Health. 2016 Dec;141:42-51
Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. Diabetes Ther. 2016 Dec;7(4):825-845
McEwan P, Bennett H, Fellows J, Priaulx J, Bergenheim K. The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. PLoS One. 2016 Sep 15;11(9):e0162441
Davies MJ, Glah D, Chubb B, Konidaris G, McEwan P. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. Pharmacoeconomics. 2016 Sep;34(9):953-66
Gordon J, McEwan P, Sabale U, Kartman B, Wolffenbuttel BH. The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes. J Med Econ. 2016 Dec;19(12):1167-1174
McEwan P, Bennett H, Ward T, Webster S, Gordon J, Kalsekar A, Yuan Y, Brenner. The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. Eur J Gastroenterol Hepatol. 2016 Feb;28(2):173-80
Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, Verheggen BG. Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32(2):207-18
2015 Publications
Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK
McEwan P, Bennett H, Ward T, Bergenheim K. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK. Pharmacoeconomics. 2015;33(2):149-61
McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration. Med Decis Making. 2015 Jul;35(5):660-70
Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga((R))) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. Prim Care Diabetes. 2015;9(1):39-47
Foos V, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ. 2015;18(6):420-32
McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015;10(1):e0117334
McEwan P, Larsen Thorsed B, Wolden M, Jacobsen H, Evans M. Healthcare resource implications of hypoglcaemia-related hospital admissions and inpatient hypoglycaemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Res Care. 2015;3(1):e000057
Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. The cost-effectiveness of dapaglifozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015;32(7):890-8
Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J. Characterising unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27(7):804-12
Bennett H, McEwan P, Sugrue D, Jalsekar A, Yuan Y. Assessing the long-tem impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS One. 2015;10(5):e0125846
Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice
Evans M, McEwan P. Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice. J Comp Eff Res. 2015;4(3):279-286
Selvapatt N, Ward T, Bailer H, Bennett H, Thorne C, See LM, Tudor-Williams G, Thurz M, McEwan P, Brown A. Is antenatal screening for hepatitis C virus cost effective? A decade’s experience at a London centre. J Hepatol. 2015;63(4):797-804
Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model
McEwan P, Ward T, Bennett H, Bergenheim K. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Eff Resour Alloc. 2015 Aug 4;13:12
Pockett RD, Watkins J, McEwan P, Meier G. Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study. PLoS One. 2015;10(8):e0134928
Gordon JP, Evans M, Puelles J, McEwan PC. Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Ther. 2015.6(4):495-507
Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation. J Med Econ. 2015 Feb;18(2):96-105
2014 Publications
Review of utility values for economic modeling in type 2 diabetes
Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes. Value Health 2014;17(4):462-70
Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK
Bennett H, McEwan P, Bergenheim K, Gordon J. Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. Diabetes Ther. 2014;5(2):567-78
The economic burden of posttransplant events in renal transplant recipients in Europe
Chamberlain G, Baboolal K, Bennett H, Pockett RD, McEwan P, Sabater J, Sennfalt K. The economic burden of posttransplant events in renal transplant recipients in Europe. Transplantation. 2014;97(8):854-61
Evans M, McEwan P, O’Shea R, George L. Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2 : résultats d’une enquête nationale rétrospective au Royaume-Uni. Médecine des Maladies Métaboliques. 2014;8(2):177-83
Validation of the IMS CORE Diabetes Model
McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE Diabetes Model. Value Health 2014;17(6):714-24
McEwan P, Ward T, Chen C-J, Lee M-H, Yang H-I, Kim R, L’Italien G, Yuan Y. Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection. Value in Health Regional Issues. 2014; 3(0):5-11
McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. Value in Health Regional Issues. 2014;3(0):136-45
van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands. Clin Drug Investig. 2014;34(2):135-46
2013 Publications
Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4(1):27-40
Evans M, McEwan P, O’Shea R, George L, Svendsen C, Clarke A. Case note survey of T2D patients prescribed incretin therapies according to current recommendations in clinical practice. Prim Care Diabetes. 2013;7(1):83
Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom
Gordon J, Evans M, McEwan P, Bain S, Vora J. Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom. Diabetes Ther. 2013;4(1):51-66
McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model. Appl Health Econ Health Policy. 2013;11(1):53-63
McEwan P, Ward T, Yuan Y, Kim R, L’Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. Hepatology. 2013;58(1):54-64
Palmer AJ, Clarke P, Gray A, Leal J, Lloyd A, Grant D, Palmer J, Foos V, Lamotte M, Hermann W, Barhak J, Willis M, Coleman R, Zhang P, McEwan P, Betz Brown J, Gerdtham U, Huang E, Briggs A, Carlsson KS, Valentine W. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. Value Health. 2013;16(4):670-85
2012 Publications
Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis. Clin Drug Investig. 2012;32(3):189-202
A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain
Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain. J Med Econ. 2012;15(2):207-18
Monitoring progress in the management of hip fractures in South Australia, Australia
Gordon J, Pham CT, Karnon J, Crotty M. Monitoring progress in the management of hip fractures in South Australia, Australia. Arch Osteoporos. 2012;7(1-2):267-73
Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden
Granstrom O, Bergenheim K, McEwan P, Sennfalt K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden. Prim Care Diabetes. 2012;6(2):127-36
Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland. Diabetes Technol Ther. 2012;14(1):65-73
Masters S, Gordon J, Whitehead C, Davies O, Giles LC, Ratcliffe J. Coaching Older Adults and Carers to have their preferences Heard (COACH): A randomised controlled trial in an intermediate care setting (study protocol). Australas Med J. 2012;5(8):444-54
Neri L, McEwan P, Sennfalt K, Baboolal K. Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study. Health Qual Life Outcomes. 2012;10:139
Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2
Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2. Value Health. 2012;15(6):804-11
System tools for system change
Willis CD, Mitton C, Gordon J, Best A. System tools for system change. BMJ Qual Saf. 2012;21(3):250-62
2011 Publications
Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14(8):1068-77